MedTrace Logo

A Phase 1 Trial of ABI-011 in Patients With Advanced Solid Tumors or Lymphomas

NCT01163071 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2019-11-14

No results posted yet for this study

Summary

The purpose of this study is to determine the MTD and/or RP2D of ABI-011 when administered by IV on Day 1, Day 8 and Day 15 with one week of rest for patients with advanced solid tumor malignancies and lymphomas.

Conditions

Interventions

DRUG

ABI-011

ABI-011

Sponsors & Collaborators

  • Celgene Corporation

    collaborator INDUSTRY

  • Celgene

    lead INDUSTRY

Principal Investigators

  • Patricia M LoRusso, DO · Karmanos Cancer Institute Hudson-Webber Cancer Research Center

  • John Sarantopoulos, MD · Cancer Therapy Research Center at the University Health Sciences Center at San Antonio

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-03-01
Primary Completion
2011-09-23
Completion
2011-09-23

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01163071 on ClinicalTrials.gov